

GLAXOSMITHKLINE PLC

Form 6-K

November 27, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 27 November 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted securities under scheme(s) from previous return: Previous balance: 33,863\* Restated balance: -27,669

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 575,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 547,331

Name of contact: Victoria Whyte

Telephone number of contact: 020 8047 5000

\*Due to clerical error the opening balance has been restated.

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline Share Option Plan -  
Ordinary Shares

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted securities under scheme(s) from previous return: Previous balance: 2,693,951\*  
Restated balance: 2,755,483

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 532,131

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 2,223,352

Name of contact: Victoria Whyte

Telephone number of contact: 020 8047 5000

\*Due to clerical error the opening balance has been restated.

#### BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline Share Option Plan -  
ADS

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted securities under scheme(s) from previous return: 7,909,994

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 573,898

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 7,336,096

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

#### BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline plc Share Save Plan 2012

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted securities under scheme(s) from previous return: 827,306

Plus: The amount by which the block scheme(s) has been increased since the date of 5,000,000 the last return (if any increase has been applied for):

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 154,683

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 5,672,623

Name of contact: Victoria Whyte

Telephone number of contact: 020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 27, 2018

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K  
behalf of GlaxoSmithKline plc